Seroprevalence of Helicobacter pylori in rheumatoid arthritis and its relationship to pharmacotherapy;Séroprevalencia Helicobacter pylori pri reumatoidnej artritíde a jej vzt'ah k farmakoterapii

Vnitrni Lekarstvi

Volumn 50, Issue 12, 2004, Pages 911-916

  Rybár, Ivan ^a   Rovensky J ^b   Masaryk, P ^b   Mateicka F ^b   Revayova I ^b  

^a NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

^b NONE

Author keywords

Helicobacter pylori; Helicobacter pylori antibodies; Nonsteroidal anti inflammatory drugs; Rheumatoid arthritis

Indexed keywords

ANTICOAGULANT AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERION; ARTICLE; DISEASE DURATION; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; RHEUMATOID ARTHRITIS; SEROPREVALENCE;

ANTIBODIES, BACTERIAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES;

EID: 11144234948     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Grigoriadou, S., Quaraishi, A., Saravanna, J. et al.: What effect does Helicobacter pylori infection have on the risk of peptic ulceration in patients receiving NSAIDs for rheumatoid arthritis. Eur. J. Intern. Med., 13, 2002, 269-273
2. Mizokami, Y., Nrusihima, K., Shiraishi, T. et al.: Non-Helicobacter pylori ulcer disease in rheumatoid arthritis patients receiving long-term NSAID therapy. J. Gastroenterol., 35, 2000, suppl. 12, 38-41
3. Konturek, P. C., Konturek, S. J., Czesnikiewicz, M. et al.: Interaction of Helicobacter pylori (Hp) and nonsteroidal anti-inflammatory drugs (NSAID) on gastric mucosa and risk of ulceration. Med. Sci. Monit., 8, 2002, 197-209
4. Rybár, I., Masaryk, P., Mateička, F. et al.: Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori. Int. J. Clin. Pharmacol. Res., 21, 2001, 119-125
5. Kalabay, L., Fekete, B., Czirjak, L. et al.: Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not human hsp60. Helicobacter, 7, 2002, 250-256
6. Arnett, F. C., Edsworthy, S. M., Bloch, D. A. et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31, 1987, 315-324
7. Steinbrocker, O., Traeger, C. H., Batterman, R. C.: Therapeutic criteria in rheumatoid arthritis. J. Am. Med. Assoc., 140, 1949, 659-662
8. Hochberg, M. C., Chang, R. W., Dwosh, I. et al.: American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum., 35, 1992, 498-502
9. Munzova, H., Díte, P., Ševčíková, I. et al.: Helicobacter pylori a nespecifické střevní záněty. Vnitř. Lék., 46, 2000, 839-842
10. Jones, S. T. M., Clague, R. B., Eldrigde, J. et al.: Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. Br. J. Rheumatol., 30, 1991, 16-20
11. Gubbins, G. P., Schubert, T. T., Attanasio, F. et al.: Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal anti-inflammatory drugs and gold compounds. Am. J. Med., 93, 1992, 412-418
12. Showji, Y., Nozawa, R., Sato, K. et al.: Seroprevalence of Helicobacter pylori infection in patients with connective tissue disease. Microbiol. Immunol., 40, 1996, 499-503
13. Aragona, P., Magazzu, G., Macchia, G. et al.: Presence of antibodies against Helicobacter pylori and its heat shock protein 60 in the serum of patients with Sjogrens syndrome. J. Rheumatol., 26, 1999, 1306-1311
14. Theander, E., Nilsson, I., Manthorpe, R. et al.: Seroprevalence of Helicobacter pylori in primary Sjogren's syndrome. Clin. Exp. Rheumatol., 19, 2001, 633-638
15. Reinauer, S., Goerz, G., Ruzicka, T. et al.: Helicobacter pylori in patients with systemic sclerosis, detection with the 13-urea breath test and eradication. Acta Derm. Venerol., 74, 1994, 361-363
16. Fujimoto, M., Sato, S., Ihn, H. et al.: Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. Arch. Dermal. Res., 287, 1995, 581-585
17. Yazawa, N., Fujimoto, M., Kikuchi, K. et al.: High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J. Rheumatol., 4, 1998, 650-653
18. Gasbarrini, A., Massari, I., Serrichio, M. et al.: Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Digest. Dis. Sci., 43, 1998, 641-645
19. Realdi, G., Dore, M.P., Fastame, L.: Extradigestive manifestations of Helicobacter pylori infection. Fact Fiction. Digest. Dis. Sci., 44, 1999, 229-236
20. Gordon, D. A., Stein, J. L., Broder, I.: The extra-articular features of rheumatoid arthritis: A systematic analysis of 127 cases. Am. J. Med., 54, 1973, 445-452
21. Zentilin, P., Seriolo, B., Dulbecco, P. et al.: Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment. Pharmacol. Ther., 16, 2002, 1291-1299
22. Ponzetto, A., Marchet, A., Pellicano, R. et al.: Association of Helicobacter pylori infection with ischemic stroke of non-cardiac origin: the BAT.MA.N. project study. Hepatogastroenterology, 49, 2002, 631-634
23. Pietrousti, A., Diomedi, M., Silvestrini, M. et al.: Cytotoxin-asociated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation, 106, 2002, 580-584
24. Schumacher, A., Seljeflot, I., Lerkerod, A. B. et al.: Does infection with Chlamydia pneumonie and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans? Clin. Microbiol. Infect., 8, 2002, 654-661
25. Hara, K., Morita, Y., Kamihata, H. et al.: Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. Clin. Chim. Acta, 313, 2001, 87-94
26. Prasad, A., Zhu, J., Halcox, J. P. et al.: Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation, 9, 2002, 164-166
27. Taha, A. S., Sturrock, R. D.: Gold plated stomach? Ann. Rheum. Dis., 52, 1993, 89-90
28. el-Omar, E., Penman, I., Cruikshank, G. et al.: Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut, 35, 1994, 1385-1388
29. Halme, L., Rautelin, H., Leidenius, M. et al.: Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease. J. Clin. Pathol., 49, 1996, 65-67
30. Ishikawa, N., Fuchigami, T., Matsumoto, T. et al.: Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesions. Rheumatology, 41, 2002, 72-77
31. Vare, P. O., Heikus, B., Silvennoinen, J. A. et al.: Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor? Scand. J. Gastroenterol., 36, 2001, 1295-1300
32. Guslandi, M., Fanti, L., Testoni, P. A.: Helicobacter pylori seroprevalence in Crohn's disease: lack of influence by pharmacological treatment. Hepatogastroenterology, 49, 2002, 1296-1297
33. van der Veen, M. J., van der Heide, A., Kruiize, A. A. et al.: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann. Rheum. Dis., 53, 1994, 224-228